Peptide Comparison
LivagenvsBPC-157
Tetrapeptide bioregulator (Lys-Glu-Asp-Ala) that directly penetrates cell nuclei and binds double-stranded DNA to induce chromatin decondensation in senescent lymphocytes, activate ribosomal genes, inhibit enkephalin-degrading enzymes with an IC50 of 20 μM, and restore protein synthesis capacity in aging cells through selective epigenetic remodeling
The "Wolverine peptide" known for its remarkable healing properties across tendons, ligaments, muscles, and the gut.
At a Glance
Quick
comparison
Dose Range
Livagen
2–10 mg
BPC-157
250–500 mcg
Frequency
Livagen
Once daily
BPC-157
Once daily
Administration
Livagen
Intramuscular injection
BPC-157
Subcutaneous injection
Cycle Length
Livagen
8-12 weeks
BPC-157
4-6 weeks
Onset Speed
Livagen
Gradual (3-4 weeks)
BPC-157
Moderate (1-2 weeks)
Evidence Level
Livagen
Limited human trials
BPC-157
Strong preclinical (extensive animal studies)
Efficacy
Benefit
ratings
Cell Renewal
Liver Support
DNA Protection
Primary Benefit
Secondary Benefit
Additional Benefit
Technical Data
Compound
specifications
Livagen
Molecular Formula
C18H31N5O9
Molecular Weight
461.5 g/mol
Half-Life
Short plasma half-life typical of tetrapeptides; biological effects persist for weeks through epigenetic chromatin remodeling modifications; metabolized to constituent amino acids (lysine, glutamic acid, aspartic acid, alanine)
Bioavailability
Resistant to intestinal proteolysis when administered orally (weakly hydrolyzed by intestinal peptidases); efficient absorption from intramuscular injection sites; penetrates cytoplasmic and nuclear membranes to reach cell nuclei and nucleoli
CAS Number
Not assigned (research compound)
BPC-157
Molecular Formula
C62H98N16O22
Molecular Weight
1419.53 g/mol
Half-Life
4-6 hours
Bioavailability
~100% (subcutaneous)
CAS Number
137525-51-0
Protocols
Dosing
tiers
Livagen
BPC-157
Applications
Best
suited for
Livagen
Comprehensive geroprotective therapy targeting epigenetic chromatin remodeling in aging cells
Livagen is particularly well-suited for individuals focused on comprehensive geroprotective therapy targeting epigenetic chromatin remodeling in aging cells. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Supporting liver function and hepatoprotection in the context of aging
Livagen is particularly well-suited for individuals focused on supporting liver function and hepatoprotection in the context of aging. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Restoring protein synthesis and ribosomal function in elderly individuals
Livagen is particularly well-suited for individuals focused on restoring protein synthesis and ribosomal function in elderly individuals. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Khavinson bioregulator protocols for anti-aging and longevity
Livagen is particularly well-suited for individuals focused on khavinson bioregulator protocols for anti-aging and longevity. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
BPC-157
Tendon and ligament injuries
Sprains, strains, tears, tendinitis - BPC-157 accelerates collagen synthesis and tissue repair
Gut healing
IBS, leaky gut, ulcers, inflammatory bowel conditions - derived from gastric juice, it has a natural affinity for digestive tissue
Muscle injuries
Strains, post-workout recovery, chronic muscle issues - promotes angiogenesis and growth factor expression
Joint problems
Arthritis support, joint pain, cartilage issues - anti-inflammatory and regenerative properties
Post-surgical recovery
Accelerating healing after procedures - works systemically to enhance the body's repair mechanisms
Safety Profile
Side
effects
Livagen
Common
- Injection site reaction
- Mild fatigue
- Mild headache
- Digestive enzyme changes
Uncommon
- Transient flu-like symptoms
Serious
- No documented serious adverse effects
BPC-157
Common
- Injection site redness
- Mild nausea
- Dizziness
Uncommon
- Headache
- Fatigue
- Hot/cold sensations
Serious
- Allergic reaction
Research Status
Safety
& evidence
Livagen
Evidence Level
Limited human trials
FDA Status
Research compound
Safety Overview
Livagen (a liver-derived peptide extract) carries a safety profile established through decades of use in Eastern European hepatology and gastroenterology clinics. As an organ-derived extract rather than a synthetic single peptide, it contains multiple bioactive components promoting hepatocyte regeneration and cytoprotection. Adverse events are minimal in reported clinical experience—mild gastrointestinal upset occurring in <5% of patients. The compound shows no hepatotoxicity, nephrotoxicity, or immunosensitization in available safety surveillance data from thousands of patients.
Contraindications
- xKnown hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid, aspartic acid, alanine)
- xPregnancy and breastfeeding — insufficient reproductive safety data
- xActive autoimmune conditions in flare without physician supervision
- xConcurrent use of opioid medications — Livagen's enkephalinase inhibition may alter opioid metabolism
BPC-157
Evidence Level
Strong preclinical (extensive animal studies)
FDA Status
Research compound
Safety Overview
BPC-157 is a gastric pentadecapeptide with strong preclinical evidence from extensive animal studies spanning over 25 years of research. Critical limitation: BPC-157 has NOT completed Phase 3 human clinical trials. No FDA approval exists. Safety data comes primarily from rat and mouse studies, with only limited Phase 1-2 human data. Animal studies show no toxicity at therapeutic doses, but human data is insufficient for regulatory approval. The peptide is unregulated, and no standardized manufacturing or quality control requirements exist for research compounds. Individual responses may vary significantly, and serious medical supervision is essential before use, particularly if you have gastrointestinal conditions, take medications, or have pre-existing medical conditions.
Contraindications
- xPregnancy
- xBreastfeeding
- xActive cancer
- xHistory of cancer
Decision Guide
Which is
right for you?
Choose Livagen if...
- Comprehensive geroprotective therapy targeting epigenetic chromatin remodeling in aging cells
- Supporting liver function and hepatoprotection in the context of aging
- Restoring protein synthesis and ribosomal function in elderly individuals
- Khavinson bioregulator protocols for anti-aging and longevity
Choose BPC-157 if...
- Injury recovery
- Post-surgery healing
- Chronic pain management
- Gut health